Evidence map›Paper›PMID 39381137›Full record

ArticleFrontiers in aging neuroscience2024

NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

Ine Paesmans, Kristof Van Kolen, Marc Vandermeeren, Pei-Yu Shih, Dirk Wuyts, Fleur Boone, Sergio Garcia Sanchez, Karolien Grauwen, Filip Van Hauwermeiren, Nina Van Opdenbosch and 3 more

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Immune signaling and function in neurodegeneration.The Journal of clinical investigation · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Brain-Targeting siRNA Delivery to Tackle Alzheimer's Disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ine PaesmansJanssen Research and Development, Janssen Pharmaceutica NV, Johnson & Johnson Company, Beerse, Belgium.
Kristof Van KolenNeuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Marc VandermeerenNeuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Pei-Yu ShihNeuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Dirk WuytsNeuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Fleur BooneVIB Center for Inflammation Research, Ghent, Belgium.
Sergio Garcia SanchezVIB Center for Inflammation Research, Ghent, Belgium.
Karolien GrauwenJanssen Research and Development, Janssen Pharmaceutica NV, Johnson & Johnson Company, Beerse, Belgium.
Filip Van HauwermeirenJanssen Research and Development, Janssen Pharmaceutica NV, Johnson & Johnson Company, Beerse, Belgium.
Nina Van OpdenboschJanssen Research and Development, Janssen Pharmaceutica NV, Johnson & Johnson Company, Beerse, Belgium.
Mohamed LamkanfiDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Geert van LooVIB Center for Inflammation Research, Ghent, Belgium.
Astrid BottelbergsJanssen Research and Development, Janssen Pharmaceutica NV, Johnson & Johnson Company, Beerse, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neuroinflammation is widely recognized as a key factor in the pathogenesis of Alzheimer's disease (AD), alongside ß-amyloid deposition and the formation of neurofibrillary tangles. The NLR family pyrin domain containing 3 (NLRP3) inflammasome, part of the innate immune system, has been implicated in the neuropathology of both preclinical amyloid and tau transgenic models. Activation of the NLRP3 pathway involves an initial priming step, which increases the expression of Nlrp3 and interleukin (IL)-1β, followed by the assembly of the NLRP3 inflammasome complex, comprising NLRP3, ASC, and caspase-1. This assembly leads to the proteolytic maturation of the pro-inflammatory cytokines IL-1β and IL-18. Additionally, the NLRP3 inflammasome induces Gasdermin D (GSDMD) cleavage, forming membrane pores through which IL-1β and IL-18 are secreted. Inhibition of NLRP3 has been shown to enhance plaque clearance by modulating microglial activation. Furthermore, blocking NLRP3 in tau transgenic mice has been found to reduce tau phosphorylation by affecting the activity of certain tau kinases and phosphatases. Methods: In this study, organotypic brain slice cultures from P301S transgenic mice were treated with lipopolysaccharide (LPS) plus nigericin as a positive control or exposed to tau seeds (K18) to evaluate NLRP3 inflammasome activation. The effect of tau seeding on NLRP3 activity was further examined using Meso Scale Discovery (MSD) assays to measure IL1β secretion levels in the presence and absence of NLRP3 inhibitors. The role of NLRP3 activity was investigated in full-body Results: Activation of the NLRP3 pathway was observed in the mouse organotypic slice culture (OSC) model following stimulation with LPS and nigericin or exposure to tau seeds. However, Conclusion: The absence of key components of the NLRP3 inflammasome pathway did not yield a beneficial effect on tau pathology or neurodegeneration in the preclinical Tau-P301S mouse model of AD. Nonetheless, organotypic slice cultures could serve as a valuable

Indexed as

GSDMDneurodegeneration and tau pathologyNLRP3OSCsP301S

Identifiers

PMID39381137
PMCPMC11458539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.